STARPHARMA HLDG.SP.ADR/10 Market Cap ($99.13 Million)
Market Cap & Net Worth: STARPHARMA HLDG.SP.ADR/10 (PQ6A)
STARPHARMA HLDG.SP.ADR/10 market cap. STARPHARMA HLDG.SP.ADR/10 (F:PQ6A) has a market capitalization of $99.13 Million (€84.79 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #19053 globally and #1758 in its home market, demonstrating a 20.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying STARPHARMA HLDG.SP.ADR/10's stock price €4.40 by its total outstanding shares 41822478 (41.82 Million).
STARPHARMA HLDG.SP.ADR/10 Market Cap History (2021–2026)
STARPHARMA HLDG.SP.ADR/10 market cap history from 2021 to 2026. Data shows change from $384.22 Million to $194.60 Million (-10.93% CAGR). Check today's stock price for STARPHARMA HLDG.SP.ADR/10 for real-time trading data and today's change.
STARPHARMA HLDG.SP.ADR/10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how STARPHARMA HLDG.SP.ADR/10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of STARPHARMA HLDG.SP.ADR/10 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
20.31x
STARPHARMA HLDG.SP.ADR/10's market cap is 20.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $162.33 Million | $4.68 Million | -$16.15 Million | 34.67x | N/A |
| 2023 | $53.30 Million | $2.94 Million | -$15.64 Million | 18.13x | N/A |
| 2024 | $28.11 Million | $8.29 Million | -$8.16 Million | 3.39x | N/A |
| 2025 | $99.75 Million | $4.91 Million | -$9.99 Million | 20.31x | N/A |
Competitor Companies of PQ6A by Market Capitalization
Companies near STARPHARMA HLDG.SP.ADR/10 in the global market cap rankings as of November 3, 2026. Also see total assets of STARPHARMA HLDG.SP.ADR/10 for a full breakdown of the balance sheet.
Key companies related to STARPHARMA HLDG.SP.ADR/10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of STARPHARMA HLDG.SP.ADR/10 (2021–2026)
Market capitalization of STARPHARMA HLDG.SP.ADR/10 from 2021 to today. Between 2021 and today, STARPHARMA HLDG.SP.ADR/10's market cap moved from $384.22 Million to $ 194.60 Million, with a yearly change of -10.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €194.60 Million | +95.10% |
| 2025 | €99.75 Million | +254.78% |
| 2024 | €28.11 Million | -47.25% |
| 2023 | €53.30 Million | -67.17% |
| 2022 | €162.33 Million | -57.75% |
| 2021 | €384.22 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of STARPHARMA HLDG.SP.ADR/10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $99.13 Million USD |
| MoneyControl | $99.13 Million USD |
| MarketWatch | $99.13 Million USD |
| marketcap.company | $99.13 Million USD |
| Reuters | $99.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About STARPHARMA HLDG.SP.ADR/10
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more